首页> 外文期刊>CNS drugs >Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment.
【24h】

Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment.

机译:神经学上表现威尔逊氏病:流行病学,病理生理学和治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

Wilson's disease is a rare autosomal recessive disease of copper accumulation and copper toxicity, due to mutations in the ATP7B gene, which leads to a failure of copper excretion in the bile. It presents clinically primarily as liver disease, psychiatric disease, neurological disease, or a combination of these. The neurological disease is a movement disorder, with abnormalities of speech, tremor, incoordination and dystonia being common features. Diagnosis of neurologically presenting patients is usually straightforward, with Kayser-Fleischer rings and a urine copper over 100 microg/day almost invariably present. In the treatment of neurologically presenting patients, penicillamine should always be avoided, because of the high risk of permanent, drug-induced, additional neurological deterioration. A new drug we have developed, tetrathiomolybdate, given for 8-16 weeks, in combination with zinc, is our first choice for treating these patients. In the absence of availability of tetrathiomolybdate, zinc or trientine are the next best choices.
机译:威尔逊氏病是一种罕见的常染色体隐性疾病,由于铜的ATP7B基因突变导致铜积累和铜毒性,从而导致胆汁中铜排泄失败。它在临床上主要表现为肝病,精神病,神经病或这些疾病的组合。神经系统疾病是一种运动障碍,常见的特征是言语,震颤,不协调和肌张力障碍。神经系统疾病患者的诊断通常很简单,Kayser-Fleischer环和每天超过100微克的尿铜几乎总是存在。在神经系统疾病患者的治疗中,应始终避免使用青霉素,因为这种药物存在永久性的,药物诱发的,额外的神经系统恶化的高风险。我们开发的一种新药物四硫代钼酸盐与锌合用8-16周,是我们治疗这些患者的首选。在缺乏四硫代钼酸盐的情况下,锌或曲恩汀是下一个最佳选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号